Wakefield Asset Management’s Zimmer Biomet ZBH Stock Holding History

Wakefield Asset Management’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17,182	Closed	-$1.93M	–	191
2023 Q3	$1.93M	Sell	17,182 -1,247	-7%	-$158K	0.87%	41
2023 Q2	$2.68M	Buy	+18,429	New	+$2.5M	1.07%	33

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wakefield Asset Management's ZBH Position: Q4 2023 in Review

Wakefield Asset Management sold out of Zimmer Biomet (ZBH) in Q4 2023, closing a stake of 17,182 shares — an estimated $1.93M sold.

Wakefield Asset Management first reported a position in ZBH in Q2 2023 and held it in 2 quarters. The position peaked at $2.68M in Q2 2023. 1,030 funds tracked by Wall St. Rank hold ZBH as of Q4 2023.

Wakefield Asset Management reported no remaining Zimmer Biomet position as of Q4 2023 after selling out during the quarter.
Wakefield Asset Management sold 17,182 Zimmer Biomet shares in Q4 2023, an estimated $1.93M.
Wakefield Asset Management first reported a position in Zimmer Biomet in Q2 2023 and held it in 2 quarters.
Wakefield Asset Management's Zimmer Biomet position peaked at $2.68M in Q2 2023.
1,030 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2023.

Based on Wakefield Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.